In a 4 weeks double-blind, randomized, placebo-controlled trial, vildagliptin improved glycemia and inhibited glucagon levels during meal ingestion but sustained glucagon counterregulation during hypoglycemia indicating its beneficial use in T1DM as an add-on to insulin therapy without increasing the risk for hypoglycemia [33]. Here, GCG is linked to type 1 diabetes mellitus.